biosimilar
Use of Abasaglar (Biosimilar Insulin Glargine)
The patent for Lantus® (Insulin glargine) has expired and a biosimilar preparation called Abasaglar®, which has a lower cost, has been launched. It has yet to be considered in the Local medicines decision making process, guidance for use with defined patient criteria is pending.
Biosimilars – NICE resource to support the implementation of biosimilar versions of infliximab
NICE has published a new adoption resource to support the introduction of biosimilar versions of infliximab: Inflectra and Remsima. This resource has been developed for both clinicians and non-clinical staff to help manage the introduction of these biosimilar medicines into care pathways safely and effectively.